Insider Selling: Twist Bioscience Co. (NASDAQ:TWST) SVP Sells $41,452.65 in Stock

Twist Bioscience Co. (NASDAQ:TWST) SVP Paula Green sold 1,101 shares of the company’s stock in a transaction on Monday, May 5th. The stock was sold at an average price of $37.65, for a total transaction of $41,452.65. Following the completion of the transaction, the senior vice president now directly owns 129,380 shares in the company, valued at $4,871,157. This trade represents a 0.84 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Paula Green also recently made the following trade(s):

• On Wednesday, April 2nd, Paula Green sold 140 shares of Twist Bioscience stock. The shares were sold at an average price of $38.73, for a total value of $5,422.20.
• On Thursday, March 20th, Paula Green sold 291 shares of Twist Bioscience stock. The shares were sold at an average price of $41.68, for a total value of $12,128.88.
• On Thursday, March 6th, Paula Green sold 918 shares of Twist Bioscience stock. The shares were sold at an average price of $40.91, for a total transaction of $37,555.38.

Twist Bioscience Price Performance

Shares of TWST stock opened at $30.82 on Friday. The company has a quick ratio of 4.62, a current ratio of 4.96 and a debt-to-equity ratio of 0.03. Twist Bioscience Co. has a 12 month low of $30.72 and a 12 month high of $60.90. The firm has a market cap of $1.85 billion, a price-to-earnings ratio of -9.12 and a beta of 2.54. The stock has a 50-day moving average price of $38.63 and a 200 day moving average price of $43.65.

Twist Bioscience (NASDAQ:TWST) last posted its quarterly earnings results on Monday, May 5th. The company reported ($0.66) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.10). The business had revenue of $92.79 million for the quarter, compared to the consensus estimate of $92.00 million. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. Research analysts expect that Twist Bioscience Co. will post -2.12 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the stock. Guggenheim restated a “buy” rating and set a $50.00 price target on shares of Twist Bioscience in a research note on Tuesday. Barclays cut their target price on Twist Bioscience from $58.00 to $45.00 and set an “overweight” rating on the stock in a report on Thursday, April 10th. JPMorgan Chase & Co. decreased their price target on Twist Bioscience from $40.00 to $33.00 and set an “underweight” rating for the company in a research note on Tuesday. The Goldman Sachs Group lowered their price objective on Twist Bioscience from $55.00 to $48.00 and set a “buy” rating on the stock in a report on Tuesday. Finally, Scotiabank reaffirmed an “outperform” rating on shares of Twist Bioscience in a research report on Tuesday, February 4th. One analyst has rated the stock with a sell rating, one has issued a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $50.40.

Hedge Funds Weigh In On Twist Bioscience

Large investors have recently added to or reduced their stakes in the company. Arizona State Retirement System increased its stake in shares of Twist Bioscience by 1.3% in the 4th quarter. Arizona State Retirement System now owns 16,985 shares of the company’s stock valued at $789,000 after purchasing an additional 219 shares during the last quarter. Van ECK Associates Corp increased its holdings in Twist Bioscience by 56.4% in the 4th quarter. Van ECK Associates Corp now owns 740 shares of the company’s stock worth $34,000 after purchasing an additional 267 shares in the last quarter. Hillsdale Investment Management Inc. raised its position in Twist Bioscience by 0.4% in the fourth quarter. Hillsdale Investment Management Inc. now owns 78,000 shares of the company’s stock valued at $3,625,000 after purchasing an additional 300 shares during the last quarter. GAMMA Investing LLC raised its holdings in Twist Bioscience by 68.1% during the 1st quarter. GAMMA Investing LLC now owns 748 shares of the company’s stock worth $29,000 after purchasing an additional 303 shares during the last quarter. Finally, Deerfield Management Company L.P. Series C grew its holdings in Twist Bioscience by 1.7% in the fourth quarter. Deerfield Management Company L.P. Series C now owns 23,827 shares of the company’s stock worth $1,107,000 after purchasing an additional 403 shares during the period.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.